Literature DB >> 17882911

The role of anti-IgE immunoglobulin therapy in nasal polyposis: a pilot study.

Renee Penn1, Suzette Mikula.   

Abstract

BACKGROUND: Although the etiology of nasal polyposis (NP) remains unknown, emerging evidence showing elevated local IgE levels and eosinophilic infiltration suggests an allergic etiology. Given this evidence, this pilot study examined whether anti-IgE therapy is efficacious in the treatment of NP.
METHODS: Data were retrospectively collected on two groups of patients with atopic asthma and NP who underwent endoscopic sinus surgery (ESS), including a control group (n=4) and an anti-IgE treatment group (n=4), who received the anti-IgE agent, omalizumab, postoperatively. Both groups were evaluated by sinus computed tomography (CT) and nasal endoscopic examination, and comparisons were made between the groups with respect to differences in the recurrence of NP after ESS.
RESULTS: Collectively, the subjects showed a direct relationship between NP severity and pretreatment total serum IgE levels. Preoperatively, there were no differences between the groups with regard to their total serum IgE levels, sinus CT scores, and endoscopically determined NP scores. Relative to corresponding preoperative values, there was no significant improvement in the sinus CT scores in either treatment group postoperatively. In contrast, relative to preoperative values, the nasal polyp scores significantly improved in the anti-IgE group, whereas the control group showed no significant improvement.
CONCLUSION: This pilot study provides new evidence establishing that (1) endoscopic NP severity directly correlates to total serum IgE levels and (2) inclusion of anti-IgE therapy in the postpolypectomy management of atopic asthmatic individuals may reduce the severity of NP recurrence.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17882911     DOI: 10.2500/ajr.2007.21.3060

Source DB:  PubMed          Journal:  Am J Rhinol        ISSN: 1050-6586


  24 in total

Review 1.  Role of medical therapy in the management of nasal polyps.

Authors:  Isam Alobid; Joaquim Mullol
Journal:  Curr Allergy Asthma Rep       Date:  2012-04       Impact factor: 4.806

2.  Long-Term Therapy with Corticosteroids in Nasal Polyposis: A Bone Metabolism Assessment.

Authors:  M Gelardi; F Barbara; I Covelli; M A Damiani; F Plantone; A Notarnicola; B Moretti; N Quaranta; G Ciprandi
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2018-08-01

Review 3.  Off-Label Uses of Omalizumab.

Authors:  David El-Qutob
Journal:  Clin Rev Allergy Immunol       Date:  2016-02       Impact factor: 8.667

Review 4.  Current and Future Treatments of Rhinitis and Sinusitis.

Authors:  Gayatri B Patel; Robert C Kern; Jonathan A Bernstein; Park Hae-Sim; Anju T Peters
Journal:  J Allergy Clin Immunol Pract       Date:  2020-01-28

5.  Endotypes and phenotypes of chronic rhinosinusitis: a PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology.

Authors:  Cezmi A Akdis; Claus Bachert; Cemal Cingi; Mark S Dykewicz; Peter W Hellings; Robert M Naclerio; Robert P Schleimer; Dennis Ledford
Journal:  J Allergy Clin Immunol       Date:  2013-04-12       Impact factor: 10.793

Review 6.  Pharmacological Management of Chronic Rhinosinusitis: Current and Evolving Treatments.

Authors:  Daniel M Beswick; Stacey T Gray; Timothy L Smith
Journal:  Drugs       Date:  2017-10       Impact factor: 9.546

7.  Anti-immunoglobulin e therapy.

Authors:  Manav Segal; Jeffrey R Stokes; Thomas B Casale
Journal:  World Allergy Organ J       Date:  2008-10       Impact factor: 4.084

8.  Aspirin sensitivity and chronic rhinosinusitis with polyps: a fatal combination.

Authors:  Hendrik Graefe; Christina Roebke; Dirk Schäfer; Jens Eduard Meyer
Journal:  J Allergy (Cairo)       Date:  2012-08-14

9.  Are atopy and eosinophilic bronchial inflammation associated with relapsing forms of chronic rhinosinusitis with nasal polyps?

Authors:  Mona-Rita Yacoub; Matteo Trimarchi; George Cremona; Sara Dal Farra; Giuseppe Alvise Ramirez; Valentina Canti; Emanuel Della Torre; Mattia Baldini; Patrizia Pignatti; Mario Bussi; Maria Grazia Sabbadini; Angelo A Manfredi; Giselda Colombo
Journal:  Clin Mol Allergy       Date:  2015-09-11

10.  Omalizumab, an anti-immunoglobulin E antibody: state of the art.

Authors:  Cristoforo Incorvaia; Marina Mauro; Marina Russello; Chiara Formigoni; Gian Galeazzo Riario-Sforza; Erminia Ridolo
Journal:  Drug Des Devel Ther       Date:  2014-02-07       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.